HomeQuestion

Would you offer adjuvant endocrine therapy to a male with ER+ DCIS?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Would you consider adding adjuvant ribociclib for a patient who has already received 2 years of endocrine therapy and is eligible for ribociclib according to the NATALEE trial?

What adjuvant systemic therapy would you recommend for a premenopausal woman with a germline BRCA mutation who initially presented with locally advanced, HR+, HER2-negative (FISH) IDC, but was later found on surgical pathology to have HR+, HER2+ disease (IHC 3+) after neoadjuvant chemotherapy?

How would you treat a patient with bilateral breast cancer, HER2 positive on one side and HER2 negative on the contralateral side, specifically in regards to adjuvant CDK4/6i vs neratinib?

What additional risk features, if any, would sway you to offer chemotherapy in premenopausal women with ER+ HER2- node positive patients whose Oncotype is < 11?

How do you manage a delayed cutaneous reaction to docetaxel after the first cycle of adjuvant TC in early-stage HR-positive, HER2-negative breast cancer?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.

Would you offer adjuvant endocrine therapy to a male with ER+ DCIS? | Mednet